Corcept Therapeutics (CORT) Operating Expenses (2016 - 2025)
Historic Operating Expenses for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $197.4 million.
- Corcept Therapeutics' Operating Expenses rose 4521.66% to $197.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $675.6 million, marking a year-over-year increase of 3924.27%. This contributed to the annual value of $538.1 million for FY2024, which is 4345.48% up from last year.
- Per Corcept Therapeutics' latest filing, its Operating Expenses stood at $197.4 million for Q3 2025, which was up 4521.66% from $167.8 million recorded in Q2 2025.
- In the past 5 years, Corcept Therapeutics' Operating Expenses ranged from a high of $197.4 million in Q3 2025 and a low of $59.6 million during Q2 2021
- Its 5-year average for Operating Expenses is $103.3 million, with a median of $90.8 million in 2023.
- In the last 5 years, Corcept Therapeutics' Operating Expenses crashed by 277.4% in 2021 and then soared by 5098.71% in 2024.
- Over the past 5 years, Corcept Therapeutics' Operating Expenses (Quarter) stood at $62.2 million in 2021, then increased by 29.6% to $80.6 million in 2022, then increased by 28.77% to $103.7 million in 2023, then surged by 50.99% to $156.6 million in 2024, then increased by 26.04% to $197.4 million in 2025.
- Its Operating Expenses stands at $197.4 million for Q3 2025, versus $167.8 million for Q2 2025 and $153.8 million for Q1 2025.